$EOLS
Evolus Inc Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000157056220000111 Filed on August 10, 2020

Income Statement

Concept	2020 Q2	2019 Q4	2019 Q2
Revenue	$7.806M	$19.45M	$2.311M
YoY Change	237.78%
Cost Of Revenue	$1.948M	$3.640M	$660.0K
YoY Change	195.15%
Gross Profit	$5.858M	$15.81M	$1.651M
YoY Change	254.82%
Gross Profit Margin	75.04%	81.29%	71.44%
Selling, General & Admin	$17.55M	$30.29M	$34.89M
YoY Change	-49.69%	147.87%	458.45%
% of Gross Profit	299.64%	191.59%	2113.39%
Research & Development	$145.0K	$420.0K	$509.0K
YoY Change	-71.51%	-64.41%	-69.11%
% of Gross Profit	2.48%	2.66%	30.83%
Depreciation & Amortization	$1.658M	$1.470M	$978.0K
YoY Change	69.53%
% of Gross Profit	28.3%	9.3%	59.24%
Operating Expenses	$24.75M	$32.17M	$37.65M
YoY Change	-34.27%	139.9%	133.84%
Operating Profit	-$18.89M	-$16.36M	-$36.00M
YoY Change	-47.53%		123.58%
Interest Expense	-$2.240M	-$2.090M	-$1.800M
YoY Change	24.44%	-2422.22%	462.5%
% of Operating Profit
Other Income/Expense, Net	-$2.464M		-$2.412M
YoY Change	2.16%		651.4%
Pretax Income	-$21.13M	-$14.64M	-$37.79M
YoY Change	-44.1%	17.87%	130.16%
Income Tax	-$2.000K	-$130.0K	-$227.0K
% Of Pretax Income
Net Earnings	-$21.13M	-$14.51M	-$37.57M
YoY Change	-43.77%	16.64%	128.61%
Net Earnings / Revenue	-270.63%	-74.6%	-1625.57%
Basic Earnings Per Share	-$0.63
Diluted Earnings Per Share	-$0.63	-$472.0K	-$1.371M
COMMON SHARES
Basic Shares Outstanding	33.73M shares	27.43M shares	27.33M shares
Diluted Shares Outstanding	33.73M shares

Balance Sheet

Concept	2020 Q2	2019 Q4	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.75M	$129.8M	$99.93M
YoY Change	-15.19%	39.33%	129.19%
Cash & Equivalents	$29.77M	$109.9M	$30.29M
Short-Term Investments	$54.98M	$19.91M	$69.64M
Other Short-Term Assets	$4.300M	$5.300M	$3.000M
YoY Change	43.33%	341.67%	200.0%
Inventory	$10.34M	$6.407M	$11.52M
Prepaid Expenses
Receivables	$8.649M	$10.66M	$1.410M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$108.0M	$152.2M	$115.8M
YoY Change	-6.76%	61.33%	159.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.422M	$902.0K	$290.0K
YoY Change	390.34%		5700.0%
Goodwill	$21.21M	$21.21M	$21.21M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$58.02M	$59.64M	$59.21M
YoY Change	-2.01%	6.35%	5.59%
Long-Term Investments
YoY Change
Other Assets	$2.155M	$2.429M	$1.206M
YoY Change	78.69%	999.1%	5381.82%
Total Long-Term Assets	$86.55M	$88.25M	$86.96M
YoY Change	-0.47%	13.86%	12.47%
TOTAL ASSETS
Total Short-Term Assets	$108.0M	$152.2M	$115.8M
Total Long-Term Assets	$86.55M	$88.25M	$86.96M
Total Assets	$194.5M	$240.4M	$202.8M
YoY Change	-4.06%	39.92%	66.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.95M	$5.796M	$7.708M
YoY Change	42.09%	272.02%	926.36%
Accrued Expenses	$6.094M	$13.96M	$15.40M
YoY Change	-60.43%	275.47%	425.06%
Deferred Revenue		$1.709M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.46M	$24.44M	$23.11M
YoY Change	-15.77%	363.21%	527.17%
LONG-TERM LIABILITIES
Long-Term Debt	$74.17M	$73.51M	$72.86M
YoY Change	1.79%		341.59%
Other Long-Term Liabilities	$38.60M	$45.10M	$47.90M
YoY Change	-19.42%	-10.16%	-1.84%
Total Long-Term Liabilities	$74.17M	$73.51M	$72.86M
YoY Change	1.79%		11.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.46M	$24.44M	$23.11M
Total Long-Term Liabilities	$74.17M	$73.51M	$72.86M
Total Liabilities	$150.9M	$161.0M	$161.6M
YoY Change	-6.6%	84.07%	92.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$253.9M	-$213.1M	-$171.6M
YoY Change	48.0%	73.18%	73.73%
Common Stock	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.60M	$79.46M	$41.18M
YoY Change
Total Liabilities & Shareholders Equity	$194.5M	$240.4M	$202.8M
YoY Change	-4.06%	39.92%	66.3%

Cashflow Statement

Concept	2020 Q2	2019 Q4	2019 Q2
OPERATING ACTIVITIES
Net Income	-$21.13M	-$14.51M	-$37.57M
YoY Change	-43.77%	16.64%	128.61%
Depreciation, Depletion And Amortization	$1.658M	$1.470M	$978.0K
YoY Change	69.53%
Cash From Operating Activities	-$13.94M	-$15.92M	-$33.16M
YoY Change	-57.96%	32.56%	485.87%
INVESTING ACTIVITIES
Capital Expenditures	-$640.0K	-$1.140M	-$1.970M
YoY Change	-67.51%		19600.0%
Acquisitions
YoY Change
Other Investing Activities	$10.02M	$15.11M	$10.19M
YoY Change	-1.67%
Cash From Investing Activities	$9.380M	$13.98M	$8.230M
YoY Change	13.97%		-82400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-310.0K	72.73M	850.0K
YoY Change	-136.47%		-374.19%
NET CHANGE
Cash From Operating Activities	-13.94M	-15.92M	-33.16M
Cash From Investing Activities	9.380M	13.98M	8.230M
Cash From Financing Activities	-310.0K	72.73M	850.0K
Net Change In Cash	-4.870M	70.79M	-24.08M
YoY Change	-79.78%	-689.43%	302.68%
FREE CASH FLOW
Cash From Operating Activities	-$13.94M	-$15.92M	-$33.16M
Capital Expenditures	-$640.0K	-$1.140M	-$1.970M
Free Cash Flow	-$13.30M	-$14.78M	-$31.19M
YoY Change	-57.36%	23.06%	452.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38381
	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1385614
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29772000	USD
	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Newport Center Drive Suite 1200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Newport Beach
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92660
	dei	City Area Code CityAreaCode	(949)
	dei	Local Phone Number LocalPhoneNumber	284-4555
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
	dei	Trading Symbol TradingSymbol	EOLS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33748478	shares
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109892000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	54982000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	19911000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8649000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10661000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	10343000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6407000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4252000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5326000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	107998000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	152197000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1422000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	902000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3738000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4068000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58023000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	59638000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	21208000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2155000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2429000	USD
CY2020Q2	us-gaap	Assets Assets	194544000	USD
CY2019Q4	us-gaap	Assets Assets	240442000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	10952000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5796000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6094000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13960000	USD
CY2020Q2	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	1234000	USD
CY2019Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	3483000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1182000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1200000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	19462000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24439000	USD
CY2020Q2	us-gaap	Contractual Obligation ContractualObligation	35100000	USD
CY2019Q4	us-gaap	Contractual Obligation ContractualObligation	41200000	USD
CY2020Q2	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	18495000	USD
CY2019Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	17945000	USD
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	74165000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	73508000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3529000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3893000	USD
CY2020Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	190000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2020Q2	us-gaap	Liabilities Liabilities	150941000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	160985000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33748478	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33748478	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33562665	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33562665	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	297502000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	292509000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	19000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253919000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213059000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	43603000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	79457000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	194544000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240442000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7806000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2311000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18302000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2311000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1948000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	660000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6167000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	660000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	5858000	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	1651000	USD
	us-gaap	Gross Profit GrossProfit	12135000	USD
	us-gaap	Gross Profit GrossProfit	1651000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17553000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34892000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48852000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52411000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	145000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	509000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2862000	USD
CY2020Q2	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	2433000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	653000	USD
CY2019Q2	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	1269000	USD
	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	-7451000	USD
	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	6182000	USD
CY2020Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1658000	USD
CY2019Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	978000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3407000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1462000	USD
CY2020Q2	us-gaap	Restructuring Charges RestructuringCharges	2956000	USD
CY2019Q2	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	2956000	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	24745000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	37648000	USD
	us-gaap	Operating Expenses OperatingExpenses	48417000	USD
	us-gaap	Operating Expenses OperatingExpenses	62917000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18887000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-35997000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36282000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61266000	USD
CY2020Q2	us-gaap	Investment Income Net InvestmentIncomeNet	224000	USD
CY2019Q2	us-gaap	Investment Income Net InvestmentIncomeNet	615000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	598000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	1004000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2464000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2412000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4922000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3030000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21127000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37794000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40606000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63292000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-227000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	254000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14750000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-21125000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37567000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40860000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48542000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-206000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	52000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	13000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	43000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21331000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37515000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40847000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48499000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.37
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33732754	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.77
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27408774	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33726595	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27369691	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	84384000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-58000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2015000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-10975000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	75357000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	853000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2486000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37567000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	52000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	41181000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	79457000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2665000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19735000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	219000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	62606000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2328000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-21125000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-206000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	43603000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40860000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48542000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3407000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1462000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5002000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4455000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2607000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	390000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	586000	USD
	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	330000	USD
	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	523000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1290000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	889000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	190000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-14750000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-7451000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	6182000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-270000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11522000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	595000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1410000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1074000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1997000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6575000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13347000	USD
	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-382000	USD
	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-409000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-191000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41892000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52358000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	677000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	346000	USD
	us-gaap	Payments For Software PaymentsForSoftware	1463000	USD
	us-gaap	Payments For Software PaymentsForSoftware	2441000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	74668000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	94011000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	40000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	25000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36808000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71798000	USD
	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	898000	USD
	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	9213000	USD
	eols	Milestone Payments For Intangible Assets MilestonePaymentsForIntangibleAssets	0	USD
	eols	Milestone Payments For Intangible Assets MilestonePaymentsForIntangibleAssets	2000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	73906000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2205000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	522000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	795000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1420000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61283000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-80120000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-62873000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109892000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93162000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29772000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30289000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3622000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1544000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5566000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	81000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	55000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-21125000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-40860000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41892000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29772000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	54982000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-253919000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company’s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation, royalty obligations, and outcomes of legal proceedings, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company’s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, the full impact of the COVID-19 outbreak is unknown and cannot be reasonably estimated. However, where possible, management has made appropriate accounting estimates with respect to certain accounting matters, which include the fair value of royalty obligations, allowance for doubtful accounts, inventory valuation and impairment assessments of goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company’s future assessment of the magnitude and duration of the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company’s financial statements in future reporting periods.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="padding-right:9pt;margin-bottom:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Risks and Uncertainties</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2013, Evolus and Daewoong entered into an agreement (the “Daewoong Agreement”), pursuant to which, the Company has an exclusive distribution license to Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The Daewoong Agreement, and Daewoong’s rights relating to Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, are subject to litigation. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2020, the Administrative Law Judge assigned to the ITC action to which the Company is a party issued an initial determination in which the judge found a violation of Section 337 of the Tariff Act of 1930 had occurred by reason of a misappropriation of trade secrets and recommended the entry of a limited exclusion order that would prevent us from importing Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> into the United States for a period of ten years and a cease and desist order that would prevent the Company from selling Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the United States for the same period of time. A final determination by the ITC is expected to be issued in November 2020, with such final determination subject to a 60-day presidential review period before taking effect. During the presidential review period the Company would be required to pay a bond at a rate set by the ITC for any sales during the period. The amount of the bond may make any sales unattractive during the period. The Company strongly disagrees with the initial determination by the Administrative Law Judge and intends to continue to vigorously defend itself in this matter. In the event that the ITC’s final determination affirms the Administrative Law Judge’s initial determination, the Company would be prevented from importing Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> into the United States and from marketing and selling Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the United States for a period of ten years, which would materially and adversely affect the Company’s ability to generate revenue from the Company’s sole product, Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to carry out its business, and to continue as a going concern. Even if the Company is successful in having the decision modified or reversed during the presidential review or in appealing any such final determination, the Company may find it difficult or be prevented from importing, marketing or selling Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the United States during the pendency of those events. Further, any modification of the Administrative Law Judge’s initial determination in the ITC’s final determination or any final decision following any such presidential review or other appeal may nonetheless still result in restrictions on the Company’s ability to import and market and sell Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the United States, which could also materially and adversely affect the Company’s ability to generate revenue from Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to carry out its business, and to continue as a going concern. In any such event, the Company may be required to seek protection under the bankruptcy laws or may be forced to reduce, significantly restructure or discontinue its operations entirely, any of which would have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows, would cause its stock price to decline and would also result in reputational harm. Even if the Company is successful, the ITC action may result in reputational damage or other collateral consequences. In addition, it is expected that an event of default under our credit agreement with Oxford would occur after the imposition of an exclusion order and cease and desist order and Oxford would be able to declare an event of default after the exhaustion of all appeals that the Company may have or earlier. If Oxford were to declare an event of default under the credit facility and exercise its remedies, it would materially and negatively affect the Company’s business, results of operation, financial condition and could result in the Company declaring bankruptcy. See Note 7. Commitments and Contingencies for additional information regarding such litigation. </span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company commercially launched Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the United States in May 2019 and in Canada through a distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company’s business and its financial statements.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the Company’s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, the need for additional financing to achieve its goals, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent COVID-19 outbreak and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions, have adversely affected the Company’s business in a number of ways, which have resulted, and may continue to result, in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase the Company’s cost of capital and adversely affect its ability to access financing when and on terms that we desire. Any of these events could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.</span></div>
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2020Q2	eols	Accrued Coupon And Rebate Liability Current AccruedCouponAndRebateLiabilityCurrent	799000	USD
CY2019Q4	eols	Accrued Coupon And Rebate Liability Current AccruedCouponAndRebateLiabilityCurrent	1709000	USD
CY2020Q2	eols	Provisions For Accrued Volume Based Rebate And Coupon Liability ProvisionsForAccruedVolumeBasedRebateAndCouponLiability	17000	USD
CY2019Q2	eols	Provisions For Accrued Volume Based Rebate And Coupon Liability ProvisionsForAccruedVolumeBasedRebateAndCouponLiability	882000	USD
	eols	Provisions For Accrued Volume Based Rebate And Coupon Liability ProvisionsForAccruedVolumeBasedRebateAndCouponLiability	10229000	USD
	eols	Provisions For Accrued Volume Based Rebate And Coupon Liability ProvisionsForAccruedVolumeBasedRebateAndCouponLiability	882000	USD
CY2020Q2	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	1697000	USD
CY2019Q2	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	0	USD
	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	11139000	USD
	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	0	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2823000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	387000	USD
CY2020Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2607000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	171000	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2019Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2020Q2	us-gaap	Restructuring Charges RestructuringCharges	2956000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-227000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	254000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14750000	USD
CY2019Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-14402000	USD
CY2020Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	34216000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	45900000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	44683000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	50200000	USD
CY2020Q2	eols	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Payments FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments	315000	USD
CY2019Q2	eols	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Payments FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments	0	USD
	eols	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Payments FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments	898000	USD
	eols	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Payments FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments	9213000	USD
CY2020Q2	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	2433000	USD
CY2019Q2	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	1269000	USD
	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	-7451000	USD
	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	6182000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	36334000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	47169000	USD
CY2020Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	36334000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	47169000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	65025000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7002000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58023000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q2	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	86233000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7002000	USD
CY2020Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	79231000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	63491000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3853000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	59638000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2019Q4	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	84699000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3853000	USD
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	80846000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3173000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4271000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3048000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2955000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2955000	USD
CY2020Q2	eols	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	41621000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	58023000	USD
CY2020Q2	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	394000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	1353000	USD
CY2019Q2	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	1534000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	2542000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1546000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	923000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3150000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1407000	USD
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3397000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5229000	USD
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	999000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5794000	USD
CY2020Q2	eols	Accrued Coupon And Rebate Liability Current AccruedCouponAndRebateLiabilityCurrent	799000	USD
CY2019Q4	eols	Accrued Coupon And Rebate Liability Current AccruedCouponAndRebateLiabilityCurrent	1709000	USD
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	899000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1228000	USD
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6094000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13960000	USD
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	26087000	USD
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	39130000	USD
CY2020Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9783000	USD
CY2020Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000	USD
CY2020Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	835000	USD
CY2020Q2	us-gaap	Long Term Debt LongTermDebt	74165000	USD
	eols	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P36M
	eols	Lessee Operating Lease Period Of Written Notice Prior To Lease Terminate Date LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate	P12M
	eols	Lessee Operating Lease Termination Fee Period Of Rent Equivalent LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent	P6M
CY2020Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	273000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	267000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	547000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	501000	USD
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	12000	USD
CY2019Q2	us-gaap	Variable Lease Cost VariableLeaseCost	32000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	27000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	61000	USD
CY2020Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2019Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	28000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	168000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	49000	USD
CY2020Q2	us-gaap	Lease Cost LeaseCost	285000	USD
CY2019Q2	us-gaap	Lease Cost LeaseCost	327000	USD
	us-gaap	Lease Cost LeaseCost	742000	USD
	us-gaap	Lease Cost LeaseCost	611000	USD
CY2020Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2020Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	583000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1207000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1259000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1314000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1371000	USD
CY2020Q2	eols	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	115000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5849000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1138000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4711000	USD
CY2020Q2	us-gaap	Purchase Obligation PurchaseObligation	6382000	USD
CY2019Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2020Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33748478	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33748478	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	834419	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2374000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2457000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5002000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4455000	USD

Files In Submission

Name	View Source	Status
0001570562-20-000111-index-headers.html	Edgar Link	pending
0001570562-20-000111-index.html	Edgar Link	pending
0001570562-20-000111.txt	Edgar Link	pending
0001570562-20-000111-xbrl.zip	Edgar Link	pending
eols-20200630.htm	Edgar Link	pending
eols-20200630.xsd	Edgar Link	pending
eols-20200630_cal.xml	Edgar Link	unprocessable
eols-20200630_def.xml	Edgar Link	unprocessable
eols-20200630_htm.xml	Edgar Link	completed
eols-20200630_lab.xml	Edgar Link	unprocessable
eols-20200630_pre.xml	Edgar Link	unprocessable
exhibit311063020.htm	Edgar Link	pending
exhibit312063020.htm	Edgar Link	pending
exhibit321063020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus Inc Stock $eols

2020 Q2 Form 10-Q Financial Statement

#000157056220000111 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus Inc Stock $eols

2020 Q2 Form 10-Q Financial Statement

#000157056220000111 Filed on August 10, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus Inc Stock $eols